RRAS2

Across TCGA pan-cancer cohorts, RRAS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RRAS2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RRAS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RRAS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where RRAS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.679	0.879	.003	31	view →
HNSC	DFS	Tertile	IV	0.814	0.532	.004	22	view →
LSCC	DFS	Tertile	III,IV	1.000	0.355	.011	12	view →
LUAD	OS	Tertile	All	1.000	0.676	.023	3	view →
GBM	DFS	Median	All	0.572	0.780	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RRAS2–PDAC (DFS)

Open the PDAC breakdown →